<DOC>
	<DOCNO>NCT00709202</DOCNO>
	<brief_summary>The study attempt evaluate histamine analog long use treatment Meniere 's disease , betahistine , , .shows promise reverse antihistaminergic effect think involve antipsychotic induced weight gain . The investigator hypotheses therefore follow : - Youth gain developmentally inappropriate amount weight SGAs see weight stabilize even decrease betahistine augmentation compare placebo augmentation . - Betahistine augmentation SGA treat youth increase level satiety standardize meal situation decrease caloric intake.as compare placebo augmentation . - Metabolic effect betahistine augmentation SGA treat youth reflect normalization adipose distribution compare placebo augmentation , particular regard ratio visceral peripheral adipose tissue . - Betahistine augmentation population lead normalization physiologic lab value relate development metabolic syndrome compare placebo augmentation .</brief_summary>
	<brief_title>Efficacy Tolerability Study Betahistine Ameliorate Antipsychotic Associated Weight Gain Adolescents Young Adults</brief_title>
	<detailed_description>Subjects study adolescent young adult age 12 age 18 . 40 individual age 12-39 psychiatrically stabilized Cloz39ine , Olanzapine , Risperdal , Seroquel , gain 2 % weight first 6 week medication recruit participate . Subjects exclude asthma , peptic ulcer disease ( disease may exacerbate histamine analog ) prescribe medication know affect body composition metabolism currently study . Subjects randomize receive either betahistine placebo 1:1 ratio .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Betahistine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Children adolescent age 1218 diagnosis Schizophrenia , Schizoaffective Disorder , Schizophreniform , Bipolar I , Bipolar II , Bipolar NOS Psychotic Disorder NOS Patients currently treat antipsychotic diagnosis schizophrenia spectrum disorder ( include schizoaffective disorder ) , bipolar disorder , autism spectrum disorder . Patients qualify entry meet follow weight criterion : 1 . The patient gain 7 % weight since begin treatment one current antipsychotic . 2 . The patient increase 7 % weight last year treat antipsychotic . 3 . The patient BMI 30 gain 10 lbs past 8 month treat antipsychotic medication . 4 . The patient BMI 35 great current time , chart show history consistent weight gain past 1 3 year treatment antipsychotic . Subjects exclude asthma , peptic ulcer disease ( disease may exacerbate histamine analog ) , history pheochromocytoma peptic ulcer disease . Patients exclude prescribed medication know affect body weight glucoselipid metabolism , prescription counter medication take purpose weight reduction . Subjects currently treat metformin , less year show recent weight change metformin . Patients thyroid replacement therapy lipidlowering agent whose dosage change 50 % past month exclude . If relatively stable dos medication exclude . Patients lipid lower medication , thyroid replacement medication , diabetes medication , ( exclude metformin ) , must remain medication throughout period study . Females pregnant breast feeding exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>